Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19612183 | 0.95 | SMN1; SMN2 (0.55) | SMN1; SMN2GLAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL3787950 | 0.92 | CSNK2A1 (0.62) | SMN1; SMN2GLAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL11097969 | 0.86 | MAPT (0.46) | SMN1; SMN2GLAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL3790208 | 0.85 | KDM4E (0.51) | SMN1; SMN2GLAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL5477791 | 0.85 | ALDH1A1 (0.68) | SMN1; SMN2GLAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL12885024 | 0.84 | KDM4E (0.69) | SMN1; SMN2L3MBTL1ALDH1A1KDM4EATM | |
| SCHEMBL13545909 | 0.83 | PPARA (0.59) | SMN1; SMN2GLACSNK2A1BACE1ATM | |
| SCHEMBL12967963 | 0.83 | L3MBTL1 (0.69) | SMN1; SMN2GLAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL9433103 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2GLAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL11094999 | 0.82 | CSNK2A1 (0.42) | SMN1; SMN2GLAL3MBTL1TDP1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170336728-A1 | ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF | CANON KABUSHIKI KAISHA (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| EP-0599886-A4 | MACROMONOMERS HAVING REACTIVE END GROUPS. | MAXDEM INC (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0599886-A1 | MACROMONOMERS HAVING REACTIVE END GROUPS | MAXDEM INCORPORATED (US) | 1994-06-08 | — | — | EP | disclosed |
| WO-1993004099-A1 | MACROMONOMERS HAVING REACTIVE END GROUPS | MAXDEM INCORPORATED (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | SMN1; SMN2 4524/4885GLA 2514/4885L3MBTL1 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.